GERMANTOWN, Md., Oct. 28, 2019 /PRNewswire/ -- Seneca
Biopharma, Inc., (fka Neuralstem, Inc) (NASDAQ: CUR) a
clinical-stage biopharmaceutical company developing novel
treatments for diseases of unmet medical need, will present at the
7th China Renaissance Healthcare and Life Sciences
Leadership Summit to be held at the Pudong Shangri-La Hotel in
East Shanghai on October 31 – November 1.
Kenneth Carter, Ph.D., Seneca's
Executive Chairman will make a company presentation on Friday, November 1 at 3:45
p.m. China Standard Time. Dr. Carter will also be conducting
one-on-one meetings during the
healthcare summit. To schedule a one-on-one meeting, please contact
Josh Barer at josh@hibiscusbio.com.
A copy of the presentation will be available on the Events
section of Seneca's website.
Who: Kenneth Carter,
Ph.D., Executive Chairman, Seneca
Biopharma
What: Company presentation and one-on-one meetings
When: The presentation will be made on Friday, November 1 at 3:45
p.m. China Standard Time
Where: Pudong Shangri-La Hotel, East Shanghai
About Seneca Biopharma
Seneca Biopharma, Inc., is a
clinical-stage biopharmaceutical company developing novel
treatments for diseases of unmet medical need. Seneca is in the
process of finding and acquiring new assets, promising sciences and
technologies that will provide meaningful therapies for patients.
(www.seneca.bio.com)
Cautionary Statement Regarding Forward Looking
Information
This news release contains "forward-looking
statements" made pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as "expect," "anticipate,"
"intend," "plan," "believe," "seek" or "will." Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed in Seneca Biopharma's periodic reports,
including its Annual Report on Form 10-K for the year ended
December 31, 2018 as well as its
subsequent quarterly reports on Form 10-Q, filed with the
Securities and Exchange Commission (SEC). We do not assume any
obligation to update any forward-looking statements.
Contact:
Josh Barer
Hibiscus BioVentures
josh@hibiscusbio.com
View original
content:http://www.prnewswire.com/news-releases/seneca-biopharma-to-present-at-the-7th-china-renaissance-healthcare-and-life-sciences-leadership-summit-300946815.html
SOURCE Seneca Biopharma